DCP quick separation detection kit

Abstract

The invention provides a DCP quick separation detection kit, by which content of abnormal prothrombin (DCP) in a human serum sample can be quickly, accurately and quantitatively metered in vitro, so that the kit is mainly used in clinical identification and diagnosis on primary hepatocellular carcinoma (HCC), chronic liver diseases and benign hepatic space-occupying lesions.

Description

technical field [0001] The invention belongs to the sub-fields of medical devices and in vitro diagnosis. Specifically, the present invention relates to a DCP rapid separation and detection kit, and a monoclonal antibody and its hybridoma cells preferably used for the preparation of the abnormal prothrombin (DCP) rapid separation and detection kit. Background technique [0002] Hepatocellular carcinoma (HCC) is a common malignant tumor disease in the world, and its incidence is increasing year by year, and now it ranks fourth in the incidence of all tumors in the world. HCC has a high mortality rate and ranks the third leading cause of cancer death in the world. About 250,000 patients worldwide die of liver cancer cells every year. The pathogenesis of HCC is still unclear, and the lack of effective early diagnosis techniques and methods is an important reason for the high mortality of HCC. Therefore, early detection and early treatment are the keys to the survival of HCC p...

AI Technical Summary

Problems solved by technology

In the current research, there have been some different monoclonal antibodies for the diagnosis of HCC, such as MU3 and 3C10, but due to the limited recognition epitopes of monoclonal antibodies, they cannot capture all DCPs, so the detection sensitivity is low

Images